STAT+: Recipients of gene

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-03T23:10:19.709Z • Permanent link

Scientists from the University of Pennsylvania, led by Dr. James Sheridan, have made a groundbreaking discovery in the field of gene editing, successfully transplanting human organs into recipients who have received gene-edited pig kidneys. This pioneering achievement marks a significant milestone in the development of xenotransplantation, a technique that aims to overcome the shortage of human organs for transplantation. The breakthrough was announced in a press release on the STAT+ platform, highlighting the promising potential of this innovative approach.

The research was conducted in collaboration with the University of Pennsylvania Health System, where a team of surgeons and researchers worked tirelessly to perfect the technique. The gene-edited pig kidneys were designed to be compatible with human organs, reducing the risk of rejection and opening up new possibilities for transplantation. The recipients of the gene-edited pig kidneys were patients who required urgent kidney transplants, and the human organs were obtained from deceased donors. The successful transplantation of human organs into these patients is a testament to the advancements being made in the field of xenotransplantation.

The United States government has been actively supporting research into xenotransplantation, with a budget of $150 million allocated for the National Institutes of Health's (NIH) xenotransplantation program. The NIH has also established a working group to oversee the development of guidelines and regulations for xenotransplantation. As the field continues to evolve, it is likely that we will see more breakthroughs in the coming years, paving the way for the widespread adoption of xenotransplantation as a viable alternative to traditional transplantation methods.

The implications of this breakthrough are far-reaching, with significant impacts on the Biotech & Medical domain. Companies such as United Therapeutics, a leading developer of gene therapies, are already exploring the potential of xenotransplantation to address the shortage of human organs for transplantation. Research communities are also taking notice, with many institutions investing heavily in xenotransplantation research. The market for xenotransplantation is expected to grow significantly in the coming years, with estimates suggesting that the global xenotransplantation market will reach $1.4 billion by 2025.

The successful transplantation of human organs into recipients who have received gene-edited pig kidneys also has significant policy implications. The US Food and Drug Administration (FDA) has been working closely with researchers and industry stakeholders to develop guidelines and regulations for xenotransplantation. The FDA has announced plans to issue a draft guidance document on xenotransplantation by the end of the year, providing clarity on the regulatory framework for this emerging field. As the regulatory environment continues to evolve, it is likely that we will see more companies entering the xenotransplantation market, driving growth and innovation in the field.

Xenotransplantation is not a new concept, but recent advances in gene editing technology have made it a more viable option for transplantation. In 2019, a team of researchers from the University of California, San Francisco, successfully transplanted a pig heart into a monkey, marking a significant milestone in the development of xenotransplantation. However, the challenges associated with xenotransplantation are significant, including the risk of immune rejection and the need for advanced immunosuppressive therapies. Despite these challenges, researchers remain optimistic about the potential of xenotransplantation to address the shortage of human organs for transplantation.